-
Biologics: Targets and Therapy
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Novel targets for immunotherapy in glomerulonephritis
Review
(3165) Views (974) Full article downloads
Authors: Mary H Foster
Published Date September 2008
Volume 2008:2(3) Pages 531 - 545
DOI: http://dx.doi.org/10.2147/BTT.S2764
Mary H Foster
Department of Medicine and Research Service, Duke University Medical Center and Durham Veterans Affairs Medical Center, Durham, North Carolina, USA
Abstract: Glomerulonephritis is a common cause of chronic kidney disease and end stage renal failure. Current therapy relies on variably effective, nonspecific and toxic immunosuppression. Recent insights into underlying biology and disease pathogenesis in human glomerulonephritis combined with advances in the fields of inflammation and autoimmunity promise a cadre of novel targeted interventions. This review highlights the therapeutic potential of two antigens, alpha3 (IV)NC1 collagen and podocyte neutral endopeptidase, and two cell signaling and effector molecules, IgG Fc receptors and complement, judged to be particularly amenable to therapeutic manipulation in man. It is anticipated that continued dissection of pathogenesis in the diverse disorders that comprise the glomerulonephritides will provide the basis for individualized disease-specific therapy.
Keywords: glomerulonephritis, immunotherapy, Goodpasture syndrome, membranous nephropathy
Readers of this article also read:
α-L-iduronidase therapy for mucopolysaccharidosis type I
Analysis and variability of TGFβ measurements in cancer patients with skeletal metastases
Long term management of patients with cryopyrin-associated periodic syndromes (CAPS): focus on rilonacept (IL-1 Trap)
Etiology of hypercoagulable state in women with recurrent fetal loss without other causes of miscarriage from Southern Italy: new clinical target for antithrombotic therapy
Therapeutic vaccines for malignant brain tumors
Gene targeted therapeutics for liver disease in alpha-1 antitrypsin deficiency
Abatacept in difficult-to-treat juvenile idiopathic arthritis
Periosteoplasty for covering gingival recessions: Clinical results
Erratum
- Testimonials
"... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University
- Journal Indexing
See where all the Dove Press journals are indexed
- The benefits and risks of testosterone replacement therapy: a review
- Tenofovir-associated bone density loss
- Drug design with Cdc7 kinase: a potential novel cancer therapy target
- Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses




